Clinical Trial Update: Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating anti-PD-1 therapy alone or with autologous DC-CIK cell therapy in advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Anti-PD-1
• DC-CIK cell therapy

Snippet

Sponsor: Capital Medical University | Conditions: Neoplasms | Phase 1, Phase 2 | Status: COMPLETED